Mitomycin Medac

Mitomycin, the active ingredient in Mitomycin Medac, is an alkylating agent presented as a sterile solution for intravenous and intravesical use. It is used to treat bladder cancer and various solid tumors in adult patients.

GNH USA supplies Mitomycin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin is employed as an antineoplastic agent for cancers that are treated via systemic or intravesical routes.

- Bladder cancer (intravesical): reduces tumor recurrence after transurethral resection. - Gastrointestinal adenocarcinomas (intravenous): used in combination regimens to achieve tumor shrinkage. - Head and neck squamous cell carcinoma (intravenous): part of multi‑drug protocols to improve response rates.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Myelosuppression (decreased blood cell counts) - Alopecia (hair loss) - Fatigue - Urinary irritation or cystitis - Diarrhea

Serious or Rare Side Effects: - Severe bone marrow suppression leading to infection or bleeding - Pulmonary toxicity (interstitial pneumonitis) - Hemolytic‑uremic syndrome - Anaphylactic or severe allergic reactions - Renal toxicity or acute kidney injury - Severe skin reactions such as Stevens‑Johnson syndrome

Mitomycin requires careful monitoring and specific safety measures. - Monitor blood counts: perform regular complete blood count tests to detect myelosuppression. - Assess renal function: evaluate serum creatinine and urine output before and during therapy. - Evaluate pulmonary status: watch for signs of respiratory distress or cough. - Avoid use in patients with known hypersensitivity to mitomycin or related compounds. - Use effective contraception: both male and female patients should employ reliable birth control during treatment and for a defined period after. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mitomycin may interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive chemotherapy agents: increased risk of severe bone‑marrow suppression. - Combination with high‑dose radiation therapy: heightened tissue toxicity. - Co‑administration with nephrotoxic drugs (e.g., cisplatin): amplified renal injury.

Moderate Interactions (Monitor Closely): - Use with warfarin or other anticoagulants: potential for increased bleeding. - Concurrent aminoglycoside antibiotics: monitor renal function closely. - Co‑administration with agents affecting hepatic metabolism (e.g., azole antifungals): observe for altered drug clearance.